Tag

UF Innovate | Sid Martin Biotech

The Emerging Field of Regenerative Medicine: Personalized, Precision Medicine

Regenerative medicine, in conjunction with personalized medicine, is responsible for the next major paradigm shift in modern medicine. However, neither regenerative nor personalized precision medicine are subjects traditionally found in the curriculum of U.S. medical schools. As such, this emergence has been met with skepticism, doubt and confusion.

CEO of UF Startup AxoGen is appointed to EyePoint Pharmaceuticals Board of Directors

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced the appointment of Karen Zaderej to its Board of Directors. Ms. Zaderej is currently the President, Chief Executive Officer and Chair of the Board at UF Startup and Accelerate graduate AxoGen, Inc., and brings more than 35 years of biopharmaceutical and medical device experience to the role.

Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer

UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, a biotech company dedicated to fighting infectious diseases including coronaviruses, announces the appointment of Ms. Kimberly M. Murphy, member of the Board of Directors, as President and Chief Executive Officer effective June 23, 2022. Ms. Murphy brings more than 25 years of vaccine industry experience at leading pharmaceutical companies including serving as a key leader in the successful US and Global launch of Merck’s HPV/Gardasil Franchise. Ms. Murphy joined Oragenics’ Board of Directors in 2020.

Oragenics Announces Publication of Positive Data for Its Nt-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports

UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, a biotech company dedicated to fighting infectious diseases including coronavirus, announces the publication of an article co-authored by Oragenics and collaborators at Inspirevax and the National Research Council of Canada (“NRC”) Human Health Therapeutics Research Centre in Scientific Reports, a Nature journal.

Concept Companies Leads Development Efforts on Second Phase for Lacerta Therapeutics in Alachua’s Progress District

Concept Companies, a national commercial real estate developer specializing in turnkey projects, announces the commencement of the design and construction of a new 11,961-square-foot laboratory facility for Lacerta Therapeutics, Inc., a gene therapy company. The site will be located adjacent to Lacerta Therapeutics' current location in Alachua, Florida, in Copeland Park, which Lacerta has occupied since 2020.

Alcyone Presents Preclinical Data on Gene Therapy Programs With the Center for Gene Therapy at the Abigail Wexner Research Institute (AWRI) at ASGCT 2022

Sid Martin Client Alcyone Therapeutics Inc. ("Alcyone"), a biotechnology company pioneering next-generation precision gene-based therapies for complex neurological conditions, presented preclinical data showing the Company's partnered novel adeno associated virus serotype 9 (AAV9) gene therapy vector ACTX-101 safely and effectively reactivates the inactive X chromosome in a Rett syndrome mouse model and is safe in a preliminary nonhuman primate study at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting.

AGTC Announces Positive Three-Month Interim Results From Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa

UF startup and UF Innovate | Sid Martin Biotech graduate Applied Genetic Technologies Corporation (AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today reported positive three-month interim data from its ongoing Phase 2 Skyline trial of AGTC-501, a recombinant AAV viral vector-based gene therapy targeting mutations in the RPGR gene in patients with X-linked retinitis pigmentosa (XLRP).
1 2 3 18
X